Diabetes mellitus type 2 (T2DM) is a common chronic metabolic disease, compared to non-diabetics, T2DM patients have a higher risk of heart disease, and their risk of vascular diseases is twice that of non-diabetic individuals. Multiple clinical trials have confirmed that glucagon-like peptide-1 receptor agonists (GLP-1RA), in addition to their function of lowering blood glucose, can also decrease the risk of cardiovascular events in T2DM patients. This article reviews the mechanisms of GLP-1RA-mediated cardioprotection. It provides a comprehensive review of the recent progress in GLP-1RA-mediated cardiac protective mechanisms, elaborating on the protective effects of GLP-1RA on specific heart cell and further discussing its impact on heart failure (HF), provide assistance for clinical treatment of diabetic cardiomyopathy.